The immunotherapy targeting the PD-1/PD-L1 pathway has shown significant and durable clinical responses for non-small-cell lung cancer (NSCLC) patients in addition to a more favorable toxicity profile and improved tolerability than chemotherapy [7]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.